NDC 13630-0075
SolMate broad spectrum spf 8
Avobenzone, Octisalate, Octocrylene, And Oxybenzone
SolMate broad spectrum spf 8 is a Topical Aerosol, Spray in the Human Otc Drug category. It is labeled and distributed by Prime Packaging, Inc.. The primary component is Avobenzone; Octisalate; Octocrylene; Oxybenzone.
| Product ID | 13630-0075_7d667cad-1631-4255-e053-2991aa0a84a8 |
| NDC | 13630-0075 |
| Product Type | Human Otc Drug |
| Proprietary Name | SolMate broad spectrum spf 8 |
| Generic Name | Avobenzone, Octisalate, Octocrylene, And Oxybenzone |
| Dosage Form | Aerosol, Spray |
| Route of Administration | TOPICAL |
| Marketing Start Date | 2015-03-01 |
| Marketing Category | OTC MONOGRAPH FINAL / OTC MONOGRAPH FINAL |
| Application Number | part352 |
| Labeler Name | Prime Packaging, Inc. |
| Substance Name | AVOBENZONE; OCTISALATE; OCTOCRYLENE; OXYBENZONE |
| Active Ingredient Strength | 8 mg/mL; mg/mL; mg/mL; mg/mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
Packaging
NDC 13630-0075-4
177 mL in 1 CAN (13630-0075-4)
| Marketing Start Date | 2015-03-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 13630-0075-4 [13630007504]
SolMate broad spectrum spf 8 AEROSOL, SPRAY
| Marketing Category | OTC monograph final |
| Application Number | part352 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2015-03-01 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| AVOBENZONE | 8.1 mg/mL |
OpenFDA Data
| SPL SET ID: | 22bd3509-8193-4929-aac0-b36a426e4e6c |
| Manufacturer | |
| UNII |
NDC Crossover Matching brand name "SolMate broad spectrum spf 8" or generic name "Avobenzone, Octisalate, Octocrylene, And Oxybenzone"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 58443-0104 | SolMate BROAD SPECTRUM SPF 8 | SolMate BROAD SPECTRUM SPF 8 |
| 58443-0016 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 58443-0024 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 58443-0027 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 58443-0028 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 58443-0035 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 58443-0037 | Australian Gold | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 49527-709 | CLINIQUE | AVOBENZONE, OCTISALATE, OCTOCRYLENE, and OXYBENZONE |
| 11523-7053 | Coppertone Sport Sunscreen Lip Balm | avobenzone, octisalate, octocrylene, and oxybenzone |
| 13537-153 | ESIKA | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-995 | LBEL LEDERM 35 plus JOUR Facial against first signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14141-995 | LBEL LEDERM 35 plus JOUR Facial against first signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-444 | LBEL LEDERM 35plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-445 | LBEL LEDERM 35plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-014 | LBEL LEDERM 35plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-015 | LBEL LEDERM 35plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-994 | LBEL LEDERM 45 plus JOUR Facial against noticeable signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14141-994 | LBEL LEDERM 45 plus JOUR Facial against noticeable signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-991 | LBEL LEDERM 45 plus JOUR Facial against noticeable signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-446 | LBEL LEDERM 45plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-447 | LBEL LEDERM 45plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-016 | LBEL LEDERM 45plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-017 | LBEL LEDERM 45plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-754 | LBEL LEDERM 55 plus JOUR Facial against advanced signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14141-754 | LBEL LEDERM 55 plus JOUR Facial against advanced signs of aging | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13537-448 | LBEL LEDERM 55plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-019 | LBEL LEDERM 55plus Jour | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-803 | LBEL LEDERM DAY SUNSCREEN BROAD SPECTRUM SPF 15 | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14783-804 | LBEL LEDERM DAY SUNSCREEN BROAD SPECTRUM SPF 15 | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 14141-136 | LEDERM DAY SUNSCREEN BROAD SPECTRUM SPF 15 day facial SPF 15 against noticeable signs of aging all skin types | AVOBENZONE, OCTISALATE, OCTOCRYLENE, and OXYBENZONE |
| 14783-119 | LEDERM DAY SUNSCREEN BROAD SPECTRUM SPF 15 day facial SPF 15 against noticeable signs of aging all skin types | AVOBENZONE, OCTISALATE, OCTOCRYLENE, and OXYBENZONE |
| 58232-0753 | Lubriderm Daily Moisture | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 10812-979 | Neutrogena Oil Free Moisture Broad Spectrum SPF15 | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
| 13630-0075 | SolMate | Avobenzone, Octisalate, Octocrylene, and Oxybenzone |
Trademark Results [SolMate]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SOLMATE 85578863 not registered Dead/Abandoned |
1 OAK SEATTLE, LLC 2012-03-23 |
 SOLMATE 85196023 not registered Dead/Abandoned |
Tal Adam Benzion 2010-12-12 |
 SOLMATE 85152563 4684918 Live/Registered |
BIOCYCLE LABORATORIES, INC. 2010-10-14 |
 SOLMATE 77236272 3473470 Dead/Cancelled |
BISHOP, LYNN 2007-07-23 |
 SOLMATE 74652842 2375551 Dead/Cancelled |
CALIFORNIA SUNCARE, INC. 1995-03-29 |
 SOLMATE 74151148 1680188 Dead/Cancelled |
RYBAK, FRANKLYN M. 1991-03-21 |
 SOLMATE 74077025 not registered Dead/Abandoned |
Excelsior, Inc. 1990-07-10 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.